Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962873 | 1.00 | P2RX3 (0.49) | P2RX3P2RX2KMT2ADHFRPOLB | |
| SCHEMBL5669548 | 0.83 | DHFR (0.43) | P2RX3P2RX2DHFR | |
| SCHEMBL23931351 | 0.83 | P2RX3 (0.47) | P2RX3P2RX2DHFRPOLB | |
| SCHEMBL23931355 | 0.81 | P2RX3 (0.44) | P2RX3P2RX2DHFR | |
| SCHEMBL19813184 | 0.81 | P2RX3 (0.44) | P2RX3P2RX2DHFR | |
| SCHEMBL5860694 | 0.79 | P2RX3 (0.43) | P2RX3P2RX2DHFRPOLB | |
| SCHEMBL8378083 | 0.79 | P2RX3 (0.42) | P2RX3P2RX2DHFR | |
| SCHEMBL27991633 | 0.78 | P2RX3 (0.46) | P2RX3P2RX2DHFRPOLB | |
| SCHEMBL28170660 | 0.76 | KMT2A (0.44) | KMT2ADHFR | |
| SCHEMBL16966453 | 0.75 | P2RX3 (0.46) | P2RX3P2RX2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | claimed |
| CN-108697708-A | Point mutation in TRK inhibitor resistant cancers and method related to this | 洛克索肿瘤学股份有限公司 | 2018-10-23 | — | — | CN | disclosed |